| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
|---|---|---|---|---|---|---|
| 2015 | Amiodarone Induces Overexpression of Similar to Versican b to Repress the EGFR/ Gsk3b/Snail Signaling Axis during Cardiac Valve Formation of Zebrafish Embryos | Lee H.-C.; Lo H.-C.; Lo D.-M.; Su M.-Y.; Hu J.-R.; Wu C.-C.; SHENG-NAN CHANG ; Dai M.-S.; CHIA-TI TSAI ; Tsai H.-J. | PLoS ONE | 5 | 4 | |
| 2021 | High rate of invasive fungal infections after non-T cell depleted haploidentical allo-HSCT even under antifungal prophylaxis | Lien M.-Y.; Yeh S.-P.; Gau J.-P.; Wang P.-N.; Li S.-S.; Dai M.-S.; Chen T.C.; Hsieh P.-Y.; Chiou L.-W.; Huang W.-H.; Liu Y.-C.; BOR-SHENG KO ; Taiwan Blood; Marrow Transplantation Registry (TBMTR) | Bone Marrow Transplantation | 2 | 2 | |
| 2022 | Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-responders | PO-HAN LIN ; Tseng L.-M.; Lee Y.-H.; Chen S.-T.; Yeh D.-C.; Dai M.-S.; Liu L.-C.; MING-YANG WANG ; Lo C.; Chang S.; Tan K.T.; Chen S.-J.; SUNG-HSIN KUO ; Huang C.-S. | Journal of the Formosan Medical Association | 1 | 1 | |
| 2020 | Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ? 2 HER2-directed regimens: Phase III NALA trial | Saura C.; Oliveira M.; Feng Y.-H.; Dai M.-S.; Chen S.-W.; Hurvitz S.A.; Kim S.-B.; Moy B.; Delaloge S.; Gradishar W.; Masuda N.; Palacova M.; Trudeau M.E.; Mattson J.; Yap Y.S.; Hou M.-F.; De Laurentiis M.; Yeh Y.-M.; Chang H.-T.; Yau T.; Wildiers H.; Haley B.; Fagnani D.; YEN-SHEN LU ; Crown J.; Lin J.; Takahashi M.; Takano T.; Yamaguchi M.; Fujii T.; Yao B.; Bebchuk J.; Keyvanjah K.; Bryce R.; Brufsky A.; NALA Investigators | Journal of Clinical Oncology | 253 | 231 | |
| 2019 | Varlitinib downregulates HER/ERK signaling and induces apoptosis in triple negative breast cancer cells | Liu C.-Y.; Chu P.-Y.; Huang C.-T.; Chen J.-L.; Yang H.-P.; Wang W.-L.; Lau K.-Y.; Lee C.-H.; Lan T.-Y.; Huang T.-T.; PO-HAN LIN ; Dai M.-S.; Tseng L.-M. | Cancers | 19 | 17 |
